FMP
ALXN

Financial Management Professionals’s Alexion Pharmaceuticals ALXN Stock Holding History

Financial Management Professionals’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-24
Closed -$4K – 1093
2021
Q2 		$4K Buy
24
+8
+50% +$1.37K ﹤0.01% 581
2021
Q1 		$2K Hold
16
– – ﹤0.01% 608
2020
Q4 		$2K Hold
16
– – ﹤0.01% 581
2020
Q3 		$2K Hold
16
– – ﹤0.01% 542
2020
Q2 		$2K Buy
+16
New +$1.7K ﹤0.01% 529

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Financial Management Professionals's ALXN Position: Q3 2021 in Review

Financial Management Professionals sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 24 shares — an estimated $4K sold.

Financial Management Professionals first reported a position in ALXN in Q2 2020 and held it in 5 quarters. The position peaked at $4K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Financial Management Professionals reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Financial Management Professionals sold 24 Alexion Pharmaceuticals shares in Q3 2021, an estimated $4K.
  • Financial Management Professionals first reported a position in Alexion Pharmaceuticals in Q2 2020 and held it in 5 quarters.
  • Financial Management Professionals's Alexion Pharmaceuticals position peaked at $4K in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Financial Management Professionals's 13F filing for Q3 2021, filed 2 Nov 2021.